Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.
about
The spread, treatment, and prevention of HIV-1: evolution of a global pandemicComparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.Pathogenesis of human immunodeficiency virus infectionStudies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective studyNeutralization-Enhancing RF Antibodies for HIV VaccinesComplement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific MannerAntibody-Dependent Enhancement of Hepatitis C Virus InfectionMonoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophagesRapid evolution of the neutralizing antibody response to HIV type 1 infectionCommon themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.Complement-mediated, infection-enhancing antibodies in plasma from vaccinated macaques before and after inoculation with live simian immunodeficiency virus.Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infectionA weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infectionLack of infection in HIV-exposed individuals is associated with a strong CD8(+) cell noncytotoxic anti-HIV response.Virus-host interactions in HIV pathogenesis: directions for therapy.Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines.Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent iEnhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccinationAntiviral antibodies are necessary to prevent cytotoxic T-lymphocyte escape in mice infected with a coronavirusEnhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope.Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophagesNeutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathwayAutologous and heterologous neutralization analyses of primary feline immunodeficiency virus isolates.Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.
P2860
Q22241890-97C1351C-8795-4DC4-BFD9-C7407176D06BQ24538755-E1A9C6E4-ECA2-44EF-A6D2-D18D35D46259Q24634681-F7ED4422-D09E-4FEE-BDFD-67742B062247Q24681784-D740F5C4-5898-4360-AA83-5AFEB8CA8651Q24804378-B5007A55-1BF8-481A-8849-792283BE1956Q27002322-707678E4-7300-4EE5-9185-771A6F2350FAQ27485131-A42BF2B0-046D-40E6-A967-96AA41CC4A4CQ27485451-1D25E30B-F2F4-4C00-93A9-2F4B2BF6A126Q27486215-67C6AEB6-78F8-415E-B204-B304944EEC25Q29618603-1E2ECB73-FC33-4305-BCC6-F6C031D98A72Q33784692-A6FDF72C-2BEA-4D61-B85F-209827E68FE7Q33937698-33190D92-3362-4EE1-AA0F-63B153D07938Q33997410-A78DE7E4-9F16-413D-BE0F-14132B43ABC5Q34009510-13C24647-EC37-4B19-915A-BF193BED8B9CQ34949513-2BC231CB-3834-4F34-8EBD-5BA7E5FA3C66Q35129056-FF504FFB-C7EF-4B86-8924-2505ECCD7C4AQ35839932-D88D71DF-C888-4B72-A3A2-FCFDDCD6DD62Q35853761-C11D20F7-6C23-41C3-984B-67A7645A7A12Q36230737-190BDA66-8C81-4B71-8ED3-25C1B3FAB1AAQ36305326-D3AEF02B-28B2-468A-9841-EE006571D5ADQ36315122-B225DAB7-265B-4D24-8D7F-518A7876CE41Q36549107-553753B8-7305-48EE-BA17-33C6CFBF000BQ36630413-87D95934-C8F8-423E-918D-D46E52C304BEQ36650125-49C7884C-4944-4066-BD93-1B386C3261E9Q36697927-C27BB906-009E-4F90-BC0B-7D579C199EE8Q36711168-959479D7-5A2A-4437-A0DA-74E70F02280FQ36793253-D5454588-F006-40AA-A193-492A9A921571Q36797252-6F40B61D-06EC-45AB-8B92-EFA8E10E6489Q36797335-35DF676C-13E6-42F2-A1F2-0DED3568FC19Q38762054-9824DD76-F75D-49F3-810E-054DBE28362AQ39577849-5F7A6A54-6B4A-4807-BB1E-56B41094FDA3Q39810460-3C551531-517D-40E1-8642-68F0651C24B4Q40038277-7DB81CD5-EE8F-4834-81A6-795D3215C0E4
P2860
Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Serum enhancement of human imm ...... e in HIV-infected individuals.
@ast
Serum enhancement of human imm ...... e in HIV-infected individuals.
@en
type
label
Serum enhancement of human imm ...... e in HIV-infected individuals.
@ast
Serum enhancement of human imm ...... e in HIV-infected individuals.
@en
prefLabel
Serum enhancement of human imm ...... e in HIV-infected individuals.
@ast
Serum enhancement of human imm ...... e in HIV-infected individuals.
@en
P2093
P2860
P1433
P1476
Serum enhancement of human imm ...... e in HIV-infected individuals.
@en
P2093
P2860
P304
P407
P577
1990-04-01T00:00:00Z